DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 18-27

  Pancholi, Preeti ^a   Liu, Qingyan ^a   Tricoche, Nancy ^a   Pei, Zhang ^a   Perkus, Marion E ^b   Prince, Alfred M ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; FLOW CYTOMETRY; GENE TARGETING; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEROPREVALENCE; VACCINATION; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODY FORMATION; AVIPOXVIRUS; DNA PRIMERS; DNA, VIRAL; FEMALE; HEPACIVIRUS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 0033914296     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315646     Document Type: Article

References (43)

1. 1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis in the United States: the sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 1992;327: 1899-905.
2. 2. Bukh, J, Miller RH, Purcell, RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
3. 3. Guidotti LG, Ishikawa T, Hobba MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis C virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
4. 4. Oldstone MBA, Tishon A, Eddleston M, Torre JC, McKee T, Whitton JL. Vaccination to persistent viral infection. J Virol 1993;67:4372-78.
5. 5. Schultz M, Zinkernagal RM, Hengartner H. Peptide-induced anti-viral protection by cytotoxic T cells. Proc Natl Acad Sci USA 1991;88:991-93.
6. 6. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49.
7. 7. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99: 1472-77.
8. 8. Cox, WI, Tartaglia J, Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993;195: 845-50.
9. 9. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-49.
10. 10. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998;19:89-97.
11. 11. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-68.
12. 12. Davis HL, Michel ML, Mancini M, Schleef M, Whalen RG. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 1994;12:1503-9.
13. 13. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HCJ. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994;199:132-40.
14. 14. Yokoyama M, Zhang J, Whitton JL. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol 1995;69:2684-88.
15. 15. Van Doorn LJ. Molecular biology of the hepatitis C virus. J Med Virol 1994;43:345-56.
16. 16. Geissler M, Gesein A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158:1231-37.
17. 17. Inchauspe G, Vitvitski L, Major ME, et al. Plasmid DNA expressing a secreted or a non-secreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16:185-95.
18. 18. Major ME, Vitvitski L, Mink MA, et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995;69:5798-805.
19. 19. Nakano I, Maertens G, Major ME, et al. Immunization with plasmid DNA encoding hepatitis C virus envelop E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997;71:7101-9.
20. 20. Saito T, Sherman GL, Kurokohchi K, et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. Gastroenterology 1997;112:1321-30.
21. 21. Tokushige K, Watika T, Pachuk C, et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996;24:14-20.
22. 22. Encke, J, Pulitz JZ, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in amurine model. J Immunol 1998;161:4917-23.
23. 23. Shirai M, Akatsuka T, Pendelton CD, et al. Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol 1992;66:4098-106.
24. 24. Shirai M, Chen M, Arichi T, et al. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope vaccines. J Infect Dis 1996;173:24-31.
25. 25. Liu Q, Tackney C, Bhat RA, Prince AM, Zhang P. Regulated processing of hepatitis C virus core protein is linked to subcellular localization. J Virol 1997;71:657-62.
26. 26. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188:217-32.
27. 27. Panicali D, Davis SW, Mercer SR, Paoletti E. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol 1981;37:1000-10.
28. 28. Perkus ME, Kauffman EB, Taylor J, et al. Methodology of using vaccine virus to express foreign genes in tissue culture. J Tissue Cult Methods 1993;15:72-81.
29. 29. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989;63: 3829-36.
30. 30. Gillard S, Spehner D, Drillien R, Kirn A. Localization and sequence of a vaccinia virus gene required for multiplication in human cells. Proc Natl Acad Sci USA 1986;83:5573-77.
31. 31. Miyahira Y, Murata K, Rodriguez D, et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995;181: 45-54.
32. 32. Koziel MJ, Dudley D, Afdhal N, et al. HLA class-I-restricted ctotoxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-21.
33. 33. Monaco JJ. A molecular model of MHC class I restricted antigen processing. Immunol Today 1992;13:173-79.
34. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
35. 35. Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA primimg and recombinant pox virus booster immunization. Nat Med 1999;5:526-34.
36. 36. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogeneic properties of a canarypox rabies recombinant ALVAC-RG (vCp65) in non-avian species. Vaccine 1995;13:539-49.
37. 37. Leong KH, Ramsey AJ, Morin MJ, Robinson HL, Boyle DB, Ramshaw IA. Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowlpox virus. In Brown F, Chanock R, Ginsberg H, Norrby E, eds. Vaccines 95. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1996:327-31.
38. 38. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to IFN-γ. Annu Rev Immunol 1997;15:749-95.
39. 39. Botarelli P, Brunetto MR, Minutello MA, et al. T-lymphocyte response to hepatitis C virus in clinical courses of infection. Gastroenterology 1993; 104:580-87.
40. 40. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-7.
41. 41. Ferrari C, Valli A, Galati L, et al. T cell responses to structural and nonstructural hepatitis C virus antigen in peristent and self-limited hepatitis C virus infection. Hepatology 1994;19:286-95.
42. 42. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91: 1294-98.
43. 43. Maertens G, Ducatteeuw A, Preim S, et al. Therapeutic vaccination of chronically infected chimpanzees with the HCV E1 protein [oral abstract 8.6]. In: Proceedings of the 6th International Symposium on Hepatitis C and Related Viruses. Bethesda, MD: National Institutes of Health, 1999:74.